This study evaluates patient satisfaction with receiving intravenous (IV) and/or subcutaneous (SC) immunotherapy and to assess patient preference for IV immunotherapy administration versus SC immunotherapy administration either at the hospital or at home.
* Age ≥ 18 years.
* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.
* Patients is unable to consent for themselves
* Patient has not yet completed the 1st cycle of ICI-based therapy
University of Southern California
Lead sponsor
National Cancer Institute (NCI)
Collaborator
Bristol-Myers Squibb
Collaborator